Literature DB >> 30503060

A feasible method for the isolation of mesenchymal stem cells from menstrual blood and their exosomes.

Razieh Dalirfardouei1, Khadijeh Jamialahmadi2, Elahe Mahdipour3.   

Abstract

BACKGROUND: Mesenchymal stem cells (MSCs) are currently the most promising candidates in regenerative medicine. Nonetheless, there are several limitations associated with the MSC tissue source such as infrequent and invasive bone marrow sampling methods. To overcome these limitations, we have procured MSCs from the menstrual blood (MenSCs) as a non-invasive source using a straightforward and cost-effective method. Moreover, we isolated MenSCs-derived exosomes as a safe and highly effective approach to exert the paracrine effects of MSCs.
METHODS: MSCs were isolated from menstrual blood through two different culture methods: ficoll-isolated mononuclear cells (MNCs) and whole blood culture. These cells were characterized by their plastic adherence, flow cytometry analysis of the surface markers and the differentiation potential. The exosomes were isolated from conditioned media using ultracentrifugation and characterized by different microscopy techniques, western blotting, and ELISA.
RESULTS: Both Methods resulted in the rapid isolation of cells with MSC properties. However, the cellular yield of the whole blood culture method was remarkably more than MNCs culture. MenSCs also produced a substantial amount of extracellular vesicles (EVs) possessed the minimum criteria for exosome definition.
CONCLUSION: The results suggest that direct culture of whole menstrual blood cells is a high throughput, straightforward and cost-effective method for MenSCs isolation using no special growth factors. Moreover, these cells are a good producer of exosome which can offer a cell-free therapy approach.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Keywords:  Direct culture; Exosome isolation; Ficoll-hypaque centrifugation; Menstrual blood; Mesenchymal stem cells; Whole blood cells

Mesh:

Substances:

Year:  2018        PMID: 30503060     DOI: 10.1016/j.tice.2018.09.010

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  6 in total

1.  Different phenotypes and chondrogenic responses of human menstrual blood and bone marrow mesenchymal stem cells to activin A and TGF-β3.

Authors:  Ilona Uzieliene; Edvardas Bagdonas; Kazuto Hoshi; Tomoaki Sakamoto; Atsuhiko Hikita; Zivile Tachtamisevaite; Greta Rakauskiene; Giedrius Kvederas; Ali Mobasheri; Eiva Bernotiene
Journal:  Stem Cell Res Ther       Date:  2021-04-29       Impact factor: 6.832

Review 2.  Understanding menstrual blood-derived stromal/stem cells: Definition and properties. Are we rushing into their therapeutic applications?

Authors:  Alicia Sanchez-Mata; Elena Gonzalez-Muñoz
Journal:  iScience       Date:  2021-11-22

Review 3.  Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms.

Authors:  Najmeh Kaffash Farkhad; Ali Mahmoudi; Elahe Mahdipour
Journal:  Regen Ther       Date:  2022-03-22       Impact factor: 3.419

Review 4.  Non-gynaecological Applications of Menstrual-derived Stem Cells: A Systematic Review.

Authors:  Claire Galea; Nicoletta Riva; Jean Calleja-Agius
Journal:  Avicenna J Med Biotechnol       Date:  2022 Jan-Mar

Review 5.  Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine.

Authors:  Lijun Chen; Jingjing Qu; Quanhui Mei; Xin Chen; Yangxin Fang; Lu Chen; Yifei Li; Charlie Xiang
Journal:  Stem Cell Res Ther       Date:  2021-08-03       Impact factor: 6.832

6.  Osteogenic induction of menstrual blood mesenchymal stem cell by different Ferula species extracts.

Authors:  Razieh Dalirfardouei; Elahe Mahdipour; Mehrdad Iranshahi; Khadijeh Jamialahmadi
Journal:  Avicenna J Phytomed       Date:  2021 May-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.